Short-term tolerability of etoricoxib in patients with cutaneous hypersensitivity reactions to nonsteroidal anti-inflammatory drugs

Annals of Allergy, Asthma and Immunology

Volumn 95, Issue 5, 2005, Pages 438-442

  Nettis, Eustachio ^a,b   Colanardi, Maria Cristina ^a   Ferrannini, Antonio ^a   Vacca, Angelo ^a   Tursi, Alfredo ^a  

^a UNIVERSITY OF BARI   (Italy)

^b POLICLINICO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ARYLACETIC ACID DERIVATIVE; ARYLPROPIONIC ACID DERIVATIVE; BENZYDAMINE; CELECOXIB; CHLORPHENIRAMINE MALEATE; CYCLOOXYGENASE 2 INHIBITOR; ETORICOXIB; FENAMIC ACID DERIVATIVE; FLOCTAFENINE; IBUPROFEN; INDOLE DERIVATIVE; MELOXICAM; NIMESULIDE; NONSTEROID ANTIINFLAMMATORY AGENT; OXICAM DERIVATIVE; PARACETAMOL; PHENETIDINE; PLACEBO; PYRAZOLONE DERIVATIVE; ROFECOXIB; SALICYLIC ACID DERIVATIVE; SULFONANILIDE DERIVATIVE; TALC; UNCLASSIFIED DRUG; VALDECOXIB;

ADOLESCENT; ADULT; AGED; ANGIONEUROTIC EDEMA; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG TOLERABILITY; ERYTHEMA; ERYTHEMA MULTIFORME; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROVOCATION TEST; RASH; SINGLE BLIND PROCEDURE; SKIN ALLERGY; STEVENS JOHNSON SYNDROME; SYMPTOMATOLOGY; URTICARIA;

EID: 28044457457     PISSN: 10811206     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1081-1206(10)61169-6     Document Type: Article

References (24)

1. Settipane GA. Aspirin and allergic diseases: a review. Am J Med. 1983;74:102-109.
2. Szczeklik A, Gryglewski RJ, Czerniawska-Mysik G. Clinical patterns of hypersensitivity to nonsteroidal anti-inflammatory drugs and their pathogenesis. J Allergy Clin Immunol. 1977;60:276-284.
3. Quiralte J, Blanco C, Castello R, et al. Intolerance to nonsteroidal anti-inflammatory drugs: results of controlled drug challenges in 98 patients. J Allergy Clin Immunol. 1996;98:678-685.
4. Szczeklik A, Stevenson DD. Aspirin-induced asthma: advances in pathogenesis and management. J Allergy Clin Immunol. 1999;10:5-13.
5. Stevenson DD. Approach to the patient with a history of adverse reactions to aspirin or NSAIDs: diagnosis and treatment. Allergy Asthma Proc. 2000;21:25-31.
6. Nettis E, Marcandrea M, Ferrannini A, Tursi A. Tolerability of nimesulide and paracetamol in patients with NSAID-induced urticaria/angioedema. Immunopharmacol Immunotoxicol. 2001;23:343-354.
7. Andri L, Senna G, Betteli C, et al. Tolerability of nimesulide in aspirin-sensitive patients. Ann Allergy. 1994;72:29-32.
8. Nettis E, Di Paola R, Napoli G, et al. Benzydamine: an alternative nonsteroidal anti-inflammatory drug in patients with nimesulide-induced urticaria. Allergy. 2002;5:442-445.
9. Papa G, Romano A, Del Bono A, et al. Floctafenine: a valid alternative in patients with adverse reactions to nonsteroidal anti-inflammatory drugs. Ann Allergy Asthma Immunol. 1997;78:74-78.
10. Nettis E, Di Paola R, Ferrannini A, Tursi A. Meloxicam in hypersensitivity to NSAIDs. Allergy. 2001;56:803-804.
11. Nettis E, Di Paola R, Ferrannini A, Tursi A. Tolerability of rofecoxib in patients with cutaneous adverse reactions to non-steroidal anti-inflammatory drugs. Ann Allergy Asthma Immunol. 2002;88:331-334.
12. Nettis E, Colanardi MC, Ferrannini A, Tursi A. Short-term and long-term tolerability of rofecoxib in patients with prior reactions to nonsteroidal anti-inflammatory drugs. Ann Allergy Asthma Immunol. 2005;94:29-33.
13. Riendeau D, Percival MD, Brideau C, et al. Etoricoxib (MK-0663): preclinical profile and comparison with other agents that selectively inhibit cyclooxygenase-2. J Pharmacol Exp Ther. 1999;296:558-566.
14. Schumacher HR, Boice JA, Daikh DI, et al. Randomised double blind trial of etoricoxib and indometacin in treatment of acute gouty arthritis. BMJ. 2002;324:1488-1492.
15. Malmstrom K, Kotey P, Cichanowitz N, et al. Analgesic efficacy of etoricoxib in primary dysmenorrhea: results of a randomized, controlled trial. Gynecol Obstet Invest. 2003;56:65-69.
16. Matsumoto AK, Melian A, Mandel DR, et al. A randomized, controlled, clinical trial of etoricoxib in the treatment of rheumatoid arthritis. J Rheumatol. 2002;29:1623-1630.
17. Chang DJ, Desjardins PJ, King TR, et al. The analgesic efficacy of etoricoxib compared with oxycodone/acetaminophen in an acute postoperative pain model: a randomized, double-blind clinical trial. Anesth Analg. 2004;99:807-815.
18. Pallay R, Seger W, Adler J, et al. Etoricoxib reduced pain and disability and improved quality of life in patients with chronic low back pain: a 3 month, randomized, controlled trial. Scand J Rheumatol. 2004;33:257-266.
19. Berges-Gimeno MP, Camacho-Garrido E, Garcia-Rodriguez RM, et al. Rofecoxib safe in NSAID hypersensitivity. Allergy. 2001;56:1017-1018.
20. Asero R. Tolerability of rofecoxib. Allergy. 2001;56:916-917.
21. Borges MS, Capriles-Hulett A, Caballero-Fonseca F, Perez CR. Tolerability to new COX-2 inhibitors in NSAID-sensitive patients with cutaneous reactions. Ann Allergy Asthma Immunol. 2001;87:201-204.
22. Grimm V, Rakoski J, Ring J. Urticaria and angioedema induced by COX-2 inhibitors [letter]. J Allergy Clin Immunol. 2002;109:370.
23. Kelkar PD, Butterfield JH, Teaford HG. Urticaria and angioedema from cyclooxygenase-2 inhibitors. J Rheumatol. 2001;28:2553-2554.
24. Schellenberg RR, Isserow SH. Anaphylactoid reaction to a cyclooxygenase-2 inhibitor in a patient who had a reaction to cyclooxygenase-1 inhibitor [letter]. N Engl J Med. 2001;25:1856.